- Home
- MFIN vs SCPH Comparison
MFIN vs SCPH Comparison
Compare MFIN & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- SCPH
- Stock Information
- Founded
- MFIN 1995
- SCPH 2013
- Country
- MFIN United States
- SCPH United States
- Employees
- MFIN N/A
- SCPH N/A
- Industry
- MFIN Finance: Consumer Services
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- SCPH Health Care
- Exchange
- MFIN Nasdaq
- SCPH Nasdaq
- Market Cap
- MFIN 224.2M
- SCPH 173.6M
- IPO Year
- MFIN 1996
- SCPH 2017
- Fundamental
- Price
- MFIN $9.70
- SCPH $3.81
- Analyst Decision
- MFIN
- SCPH Strong Buy
- Analyst Count
- MFIN 0
- SCPH 3
- Target Price
- MFIN N/A
- SCPH $14.00
- AVG Volume (30 Days)
- MFIN 60.8K
- SCPH 301.8K
- Earning Date
- MFIN 07-29-2025
- SCPH 08-13-2025
- Dividend Yield
- MFIN 5.02%
- SCPH N/A
- EPS Growth
- MFIN N/A
- SCPH N/A
- EPS
- MFIN 1.60
- SCPH N/A
- Revenue
- MFIN $316,751,000.00
- SCPH $41,982,000.00
- Revenue This Year
- MFIN N/A
- SCPH $108.95
- Revenue Next Year
- MFIN $5.24
- SCPH $73.83
- P/E Ratio
- MFIN $5.98
- SCPH N/A
- Revenue Growth
- MFIN 13.91
- SCPH 138.10
- 52 Week Low
- MFIN $7.21
- SCPH $1.94
- 52 Week High
- MFIN $10.50
- SCPH $5.65
- Technical
- Relative Strength Index (RSI)
- MFIN 58.94
- SCPH 61.62
- Support Level
- MFIN $8.73
- SCPH $3.84
- Resistance Level
- MFIN $9.49
- SCPH $4.03
- Average True Range (ATR)
- MFIN 0.35
- SCPH 0.18
- MACD
- MFIN 0.01
- SCPH -0.05
- Stochastic Oscillator
- MFIN 100.00
- SCPH 40.58
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The company's main product is Furoscix. Furoscix consists of this patented formulation of furosemide for subcutaneous administration with wearable, portable sc2Wear Infusor for the treatment of edema in patients with heart failure.